Schedule 13D ownership disclosure
Evommune Inc
Common Stock, $0.0001 par value per share · CUSIP: 30054Y107
Event date: 2026-02-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- LSP 7 Cooperatieve U.A.Reported CIK 0001876264
Shares: 5,288,313 · Class: 14.7%
- LSP 7 Management B.V.
Shares: 5,288,313 · Class: 14.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-059504
- Form type
- SCHEDULE 13D/A
- Filer
- Evommune, Inc.
- CIK
- CIK 2044725
- Filed
- Feb 19, 2026
- Reporting period
- Feb 12, 2026
- Description
- Schedule 13D beneficial ownership